{"id":31,"date":"2024-06-28T07:06:43","date_gmt":"2024-06-28T05:06:43","guid":{"rendered":"https:\/\/www.ipsen.com\/canada\/?page_id=31"},"modified":"2024-08-21T06:28:54","modified_gmt":"2024-08-21T04:28:54","slug":"press-releases","status":"publish","type":"page","link":"https:\/\/www.ipsen.com\/canada\/press-releases\/","title":{"rendered":"Press Releases"},"content":{"rendered":"    <section class=\"sub-page-banner bg-img\" style=\"background-image:url(https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/21062834\/press-release.png)\">\n        <div class=\"container content-sec\" role=\"main\" id=\"main\">\n            <nav aria-label=\"breadcrumb\">\n            <ol class=\"breadcrumb\">\n                <li class=\"breadcrumb-item\"><a href=\"https:\/\/www.ipsen.com\/canada\">Home<\/a><\/li><li class=\"breadcrumb-item active\"><a class=\"link-pointer-events-none\" href=\"#\" aria-current=\"page\">Press Releases<\/a><\/li><\/ol>\n            <\/nav>            <h1 class=\"visible\">Press Releases<\/h1>\n            <p class=\"visible\">A comprehensive library of Ipsen media releases for investors and members of the press.<\/p>\n        <\/div>\n    <\/section>\n\n\n\n<section class=\"media-filter\">\n    <div class=\"container media-filter-inner\">\n                <h2 class=\"media-filter-title charcoal-grey\">Explore more press releases<\/h2>\n                <div class=\"media-filter-main\" id=\"search-total-div\" data-langaugecode=\"en\" data-paginationtype=\"visible\" data-loadmore=\"hidden\" data-filtertype=\"pressrelease\" data-posttype=\"press_release\"\n            data-pagination=\"visible\" data-parenttermid=\"[28,30,32,33]\">\n            <div class=\"row\">\n                <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                                        <!-- media drop down -->\n                    <div class=\"media-drop-down\">\n                        <p class=\"media-drop-heading\">Filter<\/p>\n                        <div class=\"media-dropdown-items\">\n                            <div class=\"row\">\n                                                            <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                                    <div class=\"topic-filter\">\n                                                                                <p>Topics<\/p>\n                                                                                <div class=\"mutltiselect-dropdown topic-cat-dropdown\">\n                                            <select name=\"langOpt[]\" multiple id=\"topicOpt\">\n                                                                                                <option value=\"28\">Corporate                                                <\/option>\n                                                                                                <option value=\"30\">Neuroscience                                                <\/option>\n                                                                                                <option value=\"32\">Oncology                                                <\/option>\n                                                                                                <option value=\"33\">Rare Diseases                                                <\/option>\n                                                                                            <\/select>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                                                                                                                                <div class=\"column-2 col-lg-4 col-md-4 col-sm-12\">\n                                    <div class=\"period-filter\">\n                                            <p>Period<\/p>\n                                          <div class=\"mutltiselect-dropdown year-dropdown\">\n                                            <select name=\"langOpt[]\" multiple id=\"periodOpt\">\n                                                                                            <option value=\"2025\">2025                                                                                            <option value=\"2024\">2024                                                                                            <option value=\"2023\">2023                                                                                            <option value=\"2022\">2022                                                                                            <option value=\"2021\">2021                                                                                            <option value=\"2020\">2020                                                                                            <option value=\"2019\">2019                                                                                            <option value=\"2018\">2018                                                                                            <option value=\"2017\">2017                                                                                            <option value=\"2016\">2016                                                                                        <\/select>\n                                        <\/div>\n                                    <\/div>\n                                <\/div>\n                                \n                                                                                                            <div class=\"column-3 col-lg-4 col-md-4 \">\n                                            <div class=\"filterby-filter\">\n                                                <p>Filter by<\/p>\n                                                <div class=\"input-filter\">\n                                                    <input type=\"search\" name=\"filter-by\" id=\"filter-by\"\n                                                        placeholder=\"Type a keyword\">\n                                                <\/div>\n                                                <div class=\"filter-by-dropdown\">\n                                                    <p class=\"recent\">recent search<\/p>\n                                                                                                        <ul class=\"filter-by-list\">\n                                                                                                            <\/ul>\n                                                <\/div>\n                                            <\/div>\n                                        <\/div>\n                                                                                                                              <\/div>\n                            <div class=\"reset-btn-div\">\n                                <a href=\"#\" class=\"reset-btn\">Reset<\/a>\n                            <\/div>\n                        <\/div>\n                    <\/div>\n                                        <!-- sorting section -->\n                    \t\t\t\t\t\t\n        <section class=\"media-filter\">\n            <div class=\"container media-filter-inner\">\n                <div class=\"media-filter-main\" id=\"search-total-div\" data-langaugecode=\"en\" data-paginationtype=\"visible\" data-loadmore=\"hidden\" data-filtertype=\"investor-event\" data-posttype=\"event\" data-pagination=\"visible\" data-parenttermid=\"[492,493,1810,494]\">\n                    <div class=\"row\">\n                        <div class=\"column-1 col-xl-12 col-md-12 col-sm-12\">\n                        <div class=\"sorting-sec\">\n                            <div class=\"row\">\n                                                                    <div class=\"column-1 col-xl-6 col-lg-6 col-sm-12\">\n                                        <div class=\"no-of-item-sec\">\n                                            <p>Showing: <span id=\"start-value\">1<\/span> &#8211; <span id=\"no-of-search\">05<\/span> of <span id=\"total-count\">20<\/span>\n                                                <\/p>\n                                        <\/div>\n                                    <\/div>\n                                                                <div class=\"column-2 col-xl-6 col-lg-6 col-sm-12\">\n                                                                            <div class=\"sort-input\">\n                                            <div class=\"sort-input-inner\">\n                                            <label for=\"sorting-input\">Show<\/label>\n                                                                                            <select name=\"order\" aria-label=\"5\" id=\"show-list\">\n                                                    <option value=\"05\" selected>05<\/option>\n                                                    <option value=\"10\" >10<\/option>\n                                                    <option value=\"20\" >20<\/option>\n                                                    <option value=\"30\" >30<\/option>\n                                                    <option value=\"40\" >40<\/option>\n                                                    <option value=\"50\" >50<\/option>\n                                                <\/select>\n                                            <\/div>\n                                        <\/div>\n\t\t\t\t\t\t\t\t\n                                                                                                                <div class=\"sort-input-ascending\">\n                                            <div class=\"sort-input-ascending-inner\">\n                                                <label for=\"sorting-input-ascend\">Sort<\/label>\n                                                <select name=\"sorting-input-ascend\" id=\"show-list-as\" class=\"show-list-as\">\n                                                    <option value=\"DESC\" aria-label=\"Descending\" selected>Descending<\/option>\n                                                    <option value=\"ASC\" aria-label=\"Ascending\"  >Ascending<\/option>                                                    \n                                                <\/select>\n                                            <\/div>\n                                        <\/div>                                        \n                                                                    <\/div>\n                            <\/div>\n                        <\/div>\n                        <\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\n\t\t<\/section>\n                                       \n                    <!-- Search listing include start here-->\n                    <div id=\"search-results\" class=\"story-div\">\n                        <!-- Press Release Listing start here -->\n<div class=\"story-div\" id=\"search-div\">\n\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-iqirvo-as-a-first-in-class-dual-peroxisome-proliferator-activated-receptor-treatment-for-primary-biliary-cholangitis\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/05060545\/PR_final.jpeg\" alt=\"Health Canada approves IQIRVO\u00ae as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis\" title=\"Health Canada approves IQIRVO\u00ae as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                        Rare Diseases                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Press Release Icon\" title=\"Press Release Icon\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">28 April 2025                            <!-- <span class=\"story-read-time\">6 mins read<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">28 April 2025<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Health Canada approves IQIRVO\u00ae as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Share On Social Media\" title=\"Share On Social Media\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-iqirvo-as-a-first-in-class-dual-peroxisome-proliferator-activated-receptor-treatment-for-primary-biliary-cholangitis\/&#038;title=Health Canada approves IQIRVO\u00ae as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Share on LinkedIn\" title=\"Share on LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                       <!-- <a href=\"\">\n                                <img decoding=\"async\" src=\"\" alt=\"\" title=\"\"\/>Twitter\n                            <\/a> -->\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-iqirvo-as-a-first-in-class-dual-peroxisome-proliferator-activated-receptor-treatment-for-primary-biliary-cholangitis\/&#038;p=Health Canada approves IQIRVO\u00ae as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Share on Facebook\" title=\"Share on Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-iqirvo-as-a-first-in-class-dual-peroxisome-proliferator-activated-receptor-treatment-for-primary-biliary-cholangitis\/\">\n                        <h5 class=\"blue-txt\">Health Canada approves IQIRVO\u00ae as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">IQIRVO\u00ae (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-or-ineligible-differentiated-thyroid-cancer\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/05060545\/PR_final.jpeg\" alt=\"Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer\" title=\"Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                        Oncology                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Press Release Icon\" title=\"Press Release Icon\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">04 May 2022                            <!-- <span class=\"story-read-time\">4 mins read<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">04 May 2022<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Share On Social Media\" title=\"Share On Social Media\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-or-ineligible-differentiated-thyroid-cancer\/&#038;title=Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Share on LinkedIn\" title=\"Share on LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                       <!-- <a href=\"\">\n                                <img decoding=\"async\" src=\"\" alt=\"\" title=\"\"\/>Twitter\n                            <\/a> -->\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-or-ineligible-differentiated-thyroid-cancer\/&#038;p=Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Share on Facebook\" title=\"Share on Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-or-ineligible-differentiated-thyroid-cancer\/\">\n                        <h5 class=\"blue-txt\">Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Pivotal phase III trial data showed CABOMETYX\u00ae&nbsp;demonstrated a significant improvement in progression-free survival.1<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-in-combination-with-opdivo-nivolumab-as-a-first-line-treatment-for-adults-with-advanced-or-metastatic-renal-cell-carcinoma\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/05060545\/PR_final.jpeg\" alt=\"Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) in combination with OPDIVO\u00ae (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma\" title=\"Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) in combination with OPDIVO\u00ae (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                        Oncology                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Press Release Icon\" title=\"Press Release Icon\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">20 October 2021                            <!-- <span class=\"story-read-time\">4 mins read<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">20 October 2021<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) in combination with OPDIVO\u00ae (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Share On Social Media\" title=\"Share On Social Media\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-in-combination-with-opdivo-nivolumab-as-a-first-line-treatment-for-adults-with-advanced-or-metastatic-renal-cell-carcinoma\/&#038;title=Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) in combination with OPDIVO\u00ae (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Share on LinkedIn\" title=\"Share on LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                       <!-- <a href=\"\">\n                                <img decoding=\"async\" src=\"\" alt=\"\" title=\"\"\/>Twitter\n                            <\/a> -->\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-in-combination-with-opdivo-nivolumab-as-a-first-line-treatment-for-adults-with-advanced-or-metastatic-renal-cell-carcinoma\/&#038;p=Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) in combination with OPDIVO\u00ae (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Share on Facebook\" title=\"Share on Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-ipsens-cabometyx-cabozantinib-in-combination-with-opdivo-nivolumab-as-a-first-line-treatment-for-adults-with-advanced-or-metastatic-renal-cell-carcinoma\/\">\n                        <h5 class=\"blue-txt\">Health Canada approves Ipsen\u2019s CABOMETYX\u00ae (cabozantinib) in combination with OPDIVO\u00ae (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Pivotal phase III trial data showed CABOMETYX\u00ae&nbsp;in combination with OPDIVO\u00ae&nbsp;demonstrated superior efficacy compared to sunitinib across all key endpoints, reducing the risk of death by 40 per cent,1&nbsp;giving Canadians living with kidney cancer another treatment option.<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-increlex-first-and-only-recombinant-human-insulin-like-growth-factor-1-igf-1-therapy-in-canada-for-the-treatment-of-severe-growth-failure-associated-with-ultra-rare-con\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/05060545\/PR_final.jpeg\" alt=\"Health Canada Approves INCRELEX\u00ae, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents\" title=\"Health Canada Approves INCRELEX\u00ae, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#224a81\">\n                        Rare Diseases                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Press Release Icon\" title=\"Press Release Icon\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">16 March 2021                            <!-- <span class=\"story-read-time\">7 mins read<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">16 March 2021<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Health Canada Approves INCRELEX\u00ae, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Share On Social Media\" title=\"Share On Social Media\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-increlex-first-and-only-recombinant-human-insulin-like-growth-factor-1-igf-1-therapy-in-canada-for-the-treatment-of-severe-growth-failure-associated-with-ultra-rare-con\/&#038;title=Health Canada Approves INCRELEX\u00ae, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Share on LinkedIn\" title=\"Share on LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                       <!-- <a href=\"\">\n                                <img decoding=\"async\" src=\"\" alt=\"\" title=\"\"\/>Twitter\n                            <\/a> -->\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-increlex-first-and-only-recombinant-human-insulin-like-growth-factor-1-igf-1-therapy-in-canada-for-the-treatment-of-severe-growth-failure-associated-with-ultra-rare-con\/&#038;p=Health Canada Approves INCRELEX\u00ae, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Share on Facebook\" title=\"Share on Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/health-canada-approves-increlex-first-and-only-recombinant-human-insulin-like-growth-factor-1-igf-1-therapy-in-canada-for-the-treatment-of-severe-growth-failure-associated-with-ultra-rare-con\/\">\n                        <h5 class=\"blue-txt\">Health Canada Approves INCRELEX\u00ae, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">Mississauga, ON,&nbsp;March 16, 2021 \u2013 Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX\u00ae&nbsp;(mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD),&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div>\n<div class=\"row story-row pr-card\">\n    <div class=\"column-1 col-lg-4 col-md-4 col-sm-12\">\n                        <div class=\"story-img\">\n                                            <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/ipsen-enters-into-an-option-agreement-with-iricor-and-universite-de-montreal-for-a-discovery-stage-oncology-program\/\"><img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/08\/05060545\/PR_final.jpeg\" alt=\"Ipsen enters into an option agreement with IRICoR and Universit\u00e9 de Montr\u00e9al for a discovery-stage oncology program\" title=\"Ipsen enters into an option agreement with IRICoR and Universit\u00e9 de Montr\u00e9al for a discovery-stage oncology program\"\/><\/a>\n                                    <\/div>\n            <\/div>\n    <div class=\"column-2 col-lg-8 col-md-8 col-sm-12\">\n        <div class=\"story-post\">\n            <div class=\"story-time-div\">\n                <div class=\"story-info-sec\">\n                    <button class=\"btn tag-btn\" style=\"background-color:#4e6e9a\">\n                        Corporate                    <\/button>\n                    <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/radio.png\"\n                        class=\"radio-img desk-span\" alt=\"Press Release Icon\" title=\"Press Release Icon\" width=\"auto\">\n                    <span class=\"desk-span\">&nbsp;&#8211;&nbsp;\n                        <span class=\"story-date\">04 May 2020                            <!-- <span class=\"story-read-time\">6 mins read<\/span> -->\n                        <\/span>\n                        <p class=\"mob-span\">\n                            <span class=\"story-date\">04 May 2020<\/span>\n                            <!-- <span class=\"story-read-time\"><\/span> -->\n                        <\/p>\n                <\/div>\n                                                    <div class=\"story-share-sec visible\">\n                        <div class=\"share\"  data-title=\" Ipsen enters into an option agreement with IRICoR and Universit\u00e9 de Montr\u00e9al for a discovery-stage oncology program\">\n                            <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/share-icon.png\"\n                                alt=\"Share On Social Media\" title=\"Share On Social Media\"\/>\n                        <\/div>\n                        <div class=\"share-tray hidden\">\n                                                        <a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https:\/\/www.ipsen.com\/canada\/press-releases\/ipsen-enters-into-an-option-agreement-with-iricor-and-universite-de-montreal-for-a-discovery-stage-oncology-program\/&#038;title=Ipsen enters into an option agreement with IRICoR and Universit\u00e9 de Montr\u00e9al for a discovery-stage oncology program&#038;media=\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/LinkedIn.svg\" alt=\"Share on LinkedIn\" title=\"Share on LinkedIn\"\/>LinkedIn\n                            <\/a>\n                                                       <!-- <a href=\"\">\n                                <img decoding=\"async\" src=\"\" alt=\"\" title=\"\"\/>Twitter\n                            <\/a> -->\n                                                        <a href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/www.ipsen.com\/canada\/press-releases\/ipsen-enters-into-an-option-agreement-with-iricor-and-universite-de-montreal-for-a-discovery-stage-oncology-program\/&#038;p=Ipsen enters into an option agreement with IRICoR and Universit\u00e9 de Montr\u00e9al for a discovery-stage oncology program\">\n                                <img decoding=\"async\" src=\"https:\/\/www.ipsen.com\/canada\/wp-content\/themes\/ipsen-main\/dist\/images\/Facebook.svg\" alt=\"Share on Facebook\" title=\"Share on Facebook\" \/>Facebook\n                            <\/a>\n                                                    <\/div>\n                    <\/div>\n                            <\/div>\n            <div class=\"story-post-content\">\n                    <a href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/ipsen-enters-into-an-option-agreement-with-iricor-and-universite-de-montreal-for-a-discovery-stage-oncology-program\/\">\n                        <h5 class=\"blue-txt\">Ipsen enters into an option agreement with IRICoR and Universit\u00e9 de Montr\u00e9al for a discovery-stage oncology program<\/h5>\n                    <\/a>\n                    <p class=\"second-post-para\">PARIS, France, and MONTREAL, Canada, 04 May 2020&nbsp;\u2014 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Universit\u00e9 de Montr\u00e9al, today announced they entered into an option agreement&#8230;<\/p>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/div>\n\t\t\n<\/div>\n<br>\n\t\t\t<div class=\"pagination\"><span class='page-numbers current'>1<\/span><a class='page-numbers' onclick='paginationClick(2)'>2<\/a><span class='page-numbers dots'>&#8230;<\/span><a class='page-numbers' onclick='paginationClick(4)'>4<\/a><a class='next page-numbers' onclick='paginationClick(2)'><\/a><\/div><\/div>\n<!-- Press Release Listing Ends here -->\n                        <!-- Search listing include end here-->\n                    <\/div>\n                <\/div>\n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-31","page","type-page","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen media releases<\/title>\n<meta name=\"description\" content=\"A comprehensive feed of Ipsen media releases intended for investors and members of the press, plus contact details for press liaison.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/canada\/press-releases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen media releases\" \/>\n<meta property=\"og:description\" content=\"A comprehensive feed of Ipsen media releases intended for investors and members of the press, plus contact details for press liaison.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/canada\/press-releases\/\" \/>\n<meta property=\"og:site_name\" content=\"Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-21T04:28:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/press-releases\/\",\"url\":\"https:\/\/www.ipsen.com\/canada\/press-releases\/\",\"name\":\"Ipsen media releases\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/#website\"},\"datePublished\":\"2024-06-28T05:06:43+00:00\",\"dateModified\":\"2024-08-21T04:28:54+00:00\",\"description\":\"A comprehensive feed of Ipsen media releases intended for investors and members of the press, plus contact details for press liaison.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/press-releases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/canada\/press-releases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/press-releases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/canada\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Releases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/#website\",\"url\":\"https:\/\/www.ipsen.com\/canada\/\",\"name\":\"Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/canada\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/#organization\",\"name\":\"Canada\",\"url\":\"https:\/\/www.ipsen.com\/canada\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/canada\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg\",\"caption\":\"Canada\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/canada\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen media releases","description":"A comprehensive feed of Ipsen media releases intended for investors and members of the press, plus contact details for press liaison.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/canada\/press-releases\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen media releases","og_description":"A comprehensive feed of Ipsen media releases intended for investors and members of the press, plus contact details for press liaison.","og_url":"https:\/\/www.ipsen.com\/canada\/press-releases\/","og_site_name":"Canada","article_modified_time":"2024-08-21T04:28:54+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/canada\/press-releases\/","url":"https:\/\/www.ipsen.com\/canada\/press-releases\/","name":"Ipsen media releases","isPartOf":{"@id":"https:\/\/www.ipsen.com\/canada\/#website"},"datePublished":"2024-06-28T05:06:43+00:00","dateModified":"2024-08-21T04:28:54+00:00","description":"A comprehensive feed of Ipsen media releases intended for investors and members of the press, plus contact details for press liaison.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/canada\/press-releases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/canada\/press-releases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/canada\/press-releases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/canada\/"},{"@type":"ListItem","position":2,"name":"Press Releases"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/canada\/#website","url":"https:\/\/www.ipsen.com\/canada\/","name":"Canada","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/canada\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/canada\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/canada\/#organization","name":"Canada","url":"https:\/\/www.ipsen.com\/canada\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/canada\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/06\/20102823\/Logo-Ipsen-new.svg","caption":"Canada"},"image":{"@id":"https:\/\/www.ipsen.com\/canada\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/pages\/31","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/comments?post=31"}],"version-history":[{"count":4,"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/pages\/31\/revisions"}],"predecessor-version":[{"id":656,"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/pages\/31\/revisions\/656"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/canada\/wp-json\/wp\/v2\/media?parent=31"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}